About: Zotiraciclib

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Zotiraciclib (TG02) is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and .Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property. Zotiraciclib has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of gliomas.

Property	Value
dbo:abstract	Zotiraciclib (TG02) is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and .Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property. Zotiraciclib has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of gliomas. As of January 2020, zotiraciclib is being evaluated by in two separate Phase 1b clinical trials for the treatment of glioblastoma multiforme (GBM). Zotiracicib is also being developed as a potential treatment for diffuse intrinsic pontine glioma (DIPG), a rare pediatric cancer. Both forms of brain cancer are characterized by Myc overexpression. (en)
dbo:casNumber	1204918-72-8
dbo:chEMBL	1944698
dbo:fdaUniiCode	40D08182TT
dbo:kegg	D11599
dbo:pubchem	16739650
dbo:thumbnail	wiki-commons:Special:FilePath/Zotiraciclib_skeletal.svg?width=300
dbo:wikiPageID	62890489 (xsd:integer)
dbo:wikiPageLength	7558 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1033002306 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Cyclin-dependent_kinase_9 dbr:Anaplastic_astrocytoma dbr:Oral_administration dbr:Orphan_drug dbr:Glioblastoma dbr:Glioma dbr:Myc dbr:Acute_myeloid_leukemia dbr:Alvocidib dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbr:Diffuse_intrinsic_pontine_glioma dbr:Temozolomide dbc:Protein_kinase_inhibitors dbr:CDK_inhibitor dbr:CYP1A2 dbr:CYP3A4 dbr:National_Cancer_Institute dbr:Kinase_inhibitor dbr:Adastra_Pharmaceuticals dbr:Atuveciclib
dbp:atcPrefix	None (en)
dbp:c	23 (xsd:integer)
dbp:casNumber	1204918 (xsd:integer)
dbp:chembl	1944698 (xsd:integer)
dbp:chemspiderid	30689952 (xsd:integer)
dbp:h	24 (xsd:integer)
dbp:iupacName	-14 (xsd:integer)
dbp:kegg	D11599 (en)
dbp:legalStatus	Investigational (en)
dbp:metabolism	dbr:CYP1A2 dbr:CYP3A4
dbp:n	4 (xsd:integer)
dbp:o	1 (xsd:integer)
dbp:proteinBound	>99% (en)
dbp:pubchem	16739650 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:smiles	CN1C/C=C\CCOc2cccc-c3ccncNc4ccccC1 (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	VXBAJLGYBMTJCY-IHWYPQMZSA-N (en)
dbp:synonyms	TG02, SB1317 (en)
dbp:unii	40 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:As_of dbt:Citation_needed dbt:Clarify dbt:Infobox_drug dbt:Reflist
dct:subject	dbc:Protein_kinase_inhibitors
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Zotiraciclib (TG02) is a potent oral spectrum selective kinase inhibitor for the treatment of cancer. It was discovered in Singapore by S*BIO Pte Ltd and falls under the category of small molecule macrocycles. It crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and .Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property. Zotiraciclib has been granted orphan drug designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of gliomas. (en)
rdfs:label	Zotiraciclib (en)
owl:sameAs	wikidata:Zotiraciclib https://global.dbpedia.org/id/2Xvgz
prov:wasDerivedFrom	wikipedia-en:Zotiraciclib?oldid=1033002306&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Zotiraciclib_skeletal.svg
foaf:isPrimaryTopicOf	wikipedia-en:Zotiraciclib
is dbo:wikiPageWikiLink of	dbr:CDK_inhibitor
is foaf:primaryTopic of	wikipedia-en:Zotiraciclib

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License